⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CDTX News
Cidara Therapeutics, Inc.
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
globenewswire.com
CDTX
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
prnewswire.com
THS
CDTX
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights
prnewswire.com
RPTX
SEE
CDTX
MRSN
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
prnewswire.com
CDTX
MRSN
HOLX
Shareholder Alert: The Ademi Firm investigates whether Cidara Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
prnewswire.com
CDTX
CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders
businesswire.com
CDTX
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
businesswire.com
MRK
CDTX
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
globenewswire.com
CDTX
Cidara Therapeutics to Participate in November Investor Conferences
globenewswire.com
CDTX
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
globenewswire.com
CDTX